logo-loader
viewInnoCan Pharma

InnoCan Pharma launches production of Relief & Go CBD Spray in Portugal

The Israel-based company said it plans to start shipping product internationally within two weeks

Shorts of InnoCan product production
nnoCan Pharma is a pharmaceutical tech company developing products that harness the unique properties of cannabinoids combined with smart delivery formulations

InnoCan Pharma (CSE:INNO) announced Friday that it has kicked off production of its Derma CBD line of commercial products in Portugal. 

The first product off the line will be InnoCan’s patent-pending Relief & Go CBD Spray, which was developed by chief technology officer, Nir Avram.

"The patent-pending unique formulation of Relief & Go CBD Spray contains CBD isolate as anti inflammatory, magnesium as muscle relaxant, [and] menthol and camphor as analgesics to provide temporary relief of muscle and joint pain, before and after sports activity,” Avram said in a statement. “I believe this is an effective product, which will be very successful in the market."

READ: Innocan Pharma amends unit price of $10M offering

The Israel-based company said it plans to start shipping product internationally within two weeks.

"The commencement of the production of our Derma CBD line is a significant milestone on the way to transforming our company from a research and development company to a commercial revenue generating enterprise,” CEO Iris Bincovich added.

“We expect to ship samples and products within 2 weeks to countries [such as the] UK, Germany, France [and the] US, among others. The anticipated revenues from our Derma Cosmetic Premium brands, Relieve & Go and Shir Beauty & Science, will result in revenue in the near future".

InnoCan Pharma, through its wholly-owned subsidiary, InnoCan Israel, is a pharmaceutical tech company developing products that harness the unique properties of cannabinoids combined with smart delivery formulations. InnoCan and Tel Aviv University are collaborating on developing a new exosome-based technology that targets both central nervous system disorders and the coronavirus (COVID-19).

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: InnoCan Pharma

Price: 0.165 CAD

CSE:INNO
Market: CSE
Market Cap: $23.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Innocan Pharma launches Derma CBD line in Europe

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has launched their CBD derma line. Bincovich discusses where it is being made and the first areas of the world it is being rolled out to. Bincovich also told gave Proactive an update...

3 weeks, 4 days ago

2 min read